579 related articles for article (PubMed ID: 36483551)
21. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
22. Using Gene Editing Approaches to Fine-Tune the Immune System.
Pavlovic K; Tristán-Manzano M; Maldonado-Pérez N; Cortijo-Gutierrez M; Sánchez-Hernández S; Justicia-Lirio P; Carmona MD; Herrera C; Martin F; Benabdellah K
Front Immunol; 2020; 11():570672. PubMed ID: 33117361
[TBL] [Abstract][Full Text] [Related]
23. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
24. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
Front Immunol; 2021; 12():714822. PubMed ID: 34367185
[TBL] [Abstract][Full Text] [Related]
25. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
26. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
27. CRISPR base editors: genome editing without double-stranded breaks.
Eid A; Alshareef S; Mahfouz MM
Biochem J; 2018 Jun; 475(11):1955-1964. PubMed ID: 29891532
[TBL] [Abstract][Full Text] [Related]
28. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
[TBL] [Abstract][Full Text] [Related]
29. Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.
Zhang J; Liu J; Yang W; Cui M; Dai B; Dong Y; Yang J; Zhang X; Liu D; Liang H; Cang M
Theriogenology; 2019 Jul; 132():1-11. PubMed ID: 30981084
[TBL] [Abstract][Full Text] [Related]
30. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
[TBL] [Abstract][Full Text] [Related]
31. Emerging advances in engineered macrophages for tumor immunotherapy.
Hu J; Yang Q; Yue Z; Liao B; Cheng H; Li W; Zhang H; Wang S; Tian Q
Cytotherapy; 2023 Mar; 25(3):235-244. PubMed ID: 36008206
[TBL] [Abstract][Full Text] [Related]
32. Gene editing for immune cell therapies.
Bailey SR; Maus MV
Nat Biotechnol; 2019 Dec; 37(12):1425-1434. PubMed ID: 31160723
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
34. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
Front Immunol; 2022; 13():865424. PubMed ID: 35784280
[TBL] [Abstract][Full Text] [Related]
35. Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Valeri A; García-Ortiz A; Castellano E; Córdoba L; Maroto-Martín E; Encinas J; Leivas A; Río P; Martínez-López J
Front Immunol; 2022; 13():953849. PubMed ID: 35990652
[TBL] [Abstract][Full Text] [Related]
36. A carrier-free multiplexed gene editing system applicable for suspension cells.
Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
[TBL] [Abstract][Full Text] [Related]
37. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
38. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
39. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.
Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J
Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719
[TBL] [Abstract][Full Text] [Related]
40. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]